J&J/Medivir’s Simeprevir Review Makes For Back-To-Back Hep C Advisory Committees
This article was originally published in The Pink Sheet Daily
Like Merck’s boceprevir and Vertex’s telaprevir in 2011, simeprevir and Gilead’s sofosbuvir both have been accepted as priority review candidates for hepatitis C therapy, and will be reviewed by FDA’s Antiviral Drugs Advisory Committee on consecutive days. A positive tone is anticipated at both panel meetings.
You may also be interested in...
Swedish hepatitis specialist Medivir aims to start Nordic marketing of its oral therapy simeprevir in 2014 and start anew as a profitable biotech with expansion prospects.
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.